Page 21 - BH-2-2

Brain & Heart Oxidative stress and neurological disorders

doi: 10.1016/S0140-6736(17)32247-X J Manag Care. 2020;26(3 Suppl):S55-S61.
64. Ha J, Choi DW, Kim KJ, et al. Association of metformin use doi: 10.37765/ajmc.2020.43012
with Alzheimer’s disease in patients with newly diagnosed
type 2 diabetes: A population-based nested case-control 76. Trivedi MH. Major depressive disorder in primary
care: Strategies for identification. J Clin Psychiatry.
study. Sci Rep. 2021;11(1):24069.
2020;81(2):UT17042BR1C.
doi: 10.1038/s41598-021-03406-5
doi: 10.4088/JCP.UT17042BR1C
65. Biag HMB, Potter LA, Wilkins V, et al. Metformin treatment
in young children with fragile X syndrome. Mol Genet 77. Gu X, Ke S, Wang Q, et al. Energy metabolism in major
Genomic Med. 2019;7(11):e956. depressive disorder: Recent advances from omics
technologies and imaging. Biomed Pharmacother.
doi: 10.1002/mgg3.956 2021;141:111869.
66. Winship IR, Dursun SM, Baker GB, et al. An overview of doi: 10.1016/j.biopha.2021.111869
animal models related to schizophrenia. Can J Psychiatry.
2019;64(1):5-17. 78. Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and
national burden of treatment-resistant depression and major
doi: 10.1177/0706743718773728 depressive disorder in the United States. J Clin Psychiatry.
67. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2021;82(2):20m13699.
2016;388(10039):86-97. doi: 10.4088/JCP.20m13699

doi: 10.1016/S0140-6736(15)01121-6 79. Dwyer JB, Aftab A, Radhakrishnan R, et al. Hormonal
68. Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments for major depressive disorder: State of the
treatments of schizophrenia. Molecules. 2018;23(8):2087. art [published correction appears in Am J Psychiatry.
2020;177(7):642] [published correction appears in
doi: 10.3390/molecules23082087
Am J Psychiatry. 2020;177(10):1009]. Am J Psychiatry.
69. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on 2020;177(8):686-705.
the identification and management of treatment-resistant doi: 10.1176/appi.ajp.2020.19080848
schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123.
80. Paris J. The mistreatment of major depressive disorder. Can
doi: 10.4088/JCP.18com12123
J Psychiatry. 2014;59(3):148-151.
70. Javitt DC. Cognitive impairment associated with
schizophrenia: From pathophysiology to treatment. Annu doi: 10.1177/070674371405900306
Rev Pharmacol Toxicol. 2023;63:119-141. 81. Chiriţă AL, Gheorman V, Bondari D, Rogoveanu I. Current
understanding of the neurobiology of major depressive
doi: 10.1146/annurev-pharmtox-051921-093250
disorder. Rom J Morphol Embryol. 2015;56(2 Suppl):651-
71. Yang AC, Tsai SJ. New targets for schizophrenia 658.
treatment beyond the dopamine hypothesis. Int J Mol Sci.
2017;18(8):1689. 82. Kang SG, Cho SE. Neuroimaging biomarkers for predicting
treatment response and recurrence of major depressive
doi: 10.3390/ijms18081689 disorder. Int J Mol Sci. 2020;21(6):2148.
72. Donegan JJ, Lodge DJ. Cell-based therapies for the treatment doi: 10.3390/ijms21062148
of schizophrenia. Brain Res. 2017;1655:262-269.
83. Hofmann SG, Gómez AF. Mindfulness-based interventions
doi: 10.1016/j.brainres.2016.08.010 for anxiety and depression. Psychiatr Clin North Am.
73. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world 2017;40(4):739-749.
effectiveness of antipsychotic treatments in a nationwide doi: 10.1016/j.psc.2017.08.008
cohort of 29 823 patients with schizophrenia. JAMA
Psychiatry. 2017;74(7):686-693. 84. Zhang Z, Zhang L, Zhang G, Jin J, Zheng Z. The effect of
CBT and its modifications for relapse prevention in major
doi: 10.1001/jamapsychiatry.2017.1322 depressive disorder: A systematic review and meta-analysis.
74. Wu Y, Yang Z, Cui S. Update research advances in the BMC Psychiatry. 2018;18(1):50.
application of transcranial magnetic stimulation in the doi: 10.1186/s12888-018-1610-5
treatment of schizophrenia. Scanning. 2022;2022:5415775.
85. Mirchandaney R, Barete R, Asarnow LD. Moderators
doi: 10.1155/2022/5415775 of cognitive behavioral treatment for insomnia on
75. Maroney M. An update on current treatment strategies and depression and anxiety outcomes. Curr Psychiatry
emerging agents for the management of schizophrenia. Am Rep. 2022;24(2):121-128.

Volume 2 Issue 2 (2024) 15 doi: 10.36922/bh.2704